KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) FCF Margin (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed FCF Margin for 16 consecutive years, with 11.32% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 3293.0% year-over-year to 11.32%, compared with a TTM value of 13.82% through Dec 2025, up 1571.0%, and an annual FY2025 reading of 13.82%, up 1571.0% over the prior year.
  • FCF Margin was 11.32% for Q4 2025 at Alnylam Pharmaceuticals, down from 23.52% in the prior quarter.
  • Across five years, FCF Margin topped out at 45.61% in Q3 2023 and bottomed at 406.55% in Q1 2025.
  • Average FCF Margin over 5 years is 47.44%, with a median of 24.7% recorded in 2023.
  • The sharpest move saw FCF Margin soared 12479bps in 2021, then plummeted -38960bps in 2025.
  • Year by year, FCF Margin stood at 42.26% in 2021, then skyrocketed by 39bps to 25.9% in 2022, then soared by 112bps to 3.03% in 2023, then plummeted by -814bps to 21.61% in 2024, then skyrocketed by 152bps to 11.32% in 2025.
  • Business Quant data shows FCF Margin for ALNY at 11.32% in Q4 2025, 23.52% in Q3 2025, and 19.81% in Q2 2025.